Teva's 2Q Earnings Move Higher on Sales
08.03.2004, 07:56 AM

Generic drug maker Teva Pharmaceutical Industries Ltd. reported Tuesday that
second-quarter profits moved higher on sales of many new products and increased
sales of its multiple sclerosis drug Copaxone.

Jerusalem-based Teva said quarterly earnings rose 9 percent to $229.5 million, or
35 cents per share, from $210.4 million, or 37 cents per share, a year ago. Results
from 2003 included a one-time gain of $73 million. Analysts surveyed by Thomson
First Call expected Teva to post earnings of 33 cents per share in the latest quarter.

Sales increased 54 percent to $1.18 billion, from $764.4 million last year, due to the
consolidation of Sicor and new generic products that were not sold in the year-ago
quarter both in the United States and Europe, as well as higher global sales of
multiple sclerosis drug Copaxone.

North American pharmaceutical sales rose 67 percent to $676 million from $405
million a year ago, manily due to sales of 17 new products that weren't sold last
year, particularly Oxycodone and Carboplatin. Pharmaceutical sales in Europe
increased 42 percent in the quarter to $274 million, due to sales of new products,
higher Copaxone sales that were due in part to the launch of the Copaxone pre-
filled syringe, and favorable currency trends.

Global in-market sales of Copaxone this quarter rose 28 percent to $226 million, as
U.S. sales increased 24 percent to $150 million.

The company said it plans to submit a written response to certain Food and Drug
Administration questions regarding Parkinson's drug Agilect in the beginning of the
fourth quarter, and Teva has requested a meeting with the FDA regarding labeling
issues.

American depositary receipts of Teva closed Monday at $29.65 on the Nasdaq
National Market, but moved up 65 cents, or 2.2 percent, to $30.30 in pre-market
activity.

SOURCE: Forbes
http://tinyurl.com/62evr

Reference:

Teva Receives Approvable Letter for AGILECT 'Rasagiline'

JERUSALEM--(BUSINESS WIRE)--July 5, 2004--Teva Pharmaceutical Industries
Ltd. (Nasdaq:TEVA) announced today that it has received an approvable letter from
the U.S. Food and Drug Administration (FDA) for once-daily AGILECT(R)
(rasagiline mesylate) as a treatment for Parkinson's disease (PD) as initial
monotherapy in early PD patients and as adjunct therapy to levodopa in moderate-
to-advanced stages of the disease. Following the approvable letter, Teva will work
together with the FDA to complete the process of receiving final approval as soon
as possible.

SNIP

SOURCE: Business Wire / BioSpace News
http://tinyurl.com/6gfjo

* * *


* * *

----------------------------------------------------------------------
To sign-off Parkinsn send a message to: mailto:[log in to unmask]
In the body of the message put: signoff parkinsn